drugset / Trial / NCT02022228
Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
Unknown
200 enrolled
Chenshiling
Comprehensive Strategic Cooperation Project of Guangdong Province and Chinese Academy of Science · collabGuangzhou Science and Technology Program key projects · collabNational Key Basic Research Development Plan of China · collabNational Natural Science Foundation of China · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk patients. However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist. Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG) for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.
Timeline
- Start
- 2012-07
- Primary completion
- 2015-12
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hCG | Unknown | 500 iu | Intramuscular |
| Subject | hCG | Unknown | 1000 iu | Intramuscular |
| Background | Triptorelin | Other / unclassified | 0.2 mg | Other |